Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
FPA-150 by Five Prime Therapeutics for Epithelial Ovarian Cancer: Likelihood of Approval
FPA-150 is under clinical development by Five Prime Therapeutics and currently in Phase I for Epithelial Ovarian Cancer. According to...